Details of the Drug Formulations

General Information of Drug (ID: DMGDKXN)

Drug Name
Sitagliptin Drug Info
Synonyms
486460-32-6; Januvia; Xelevia; Sitagliptan; MK-0431; UNII-QFP0P1DV7Z; Tesavel; QFP0P1DV7Z; (3R)-3-AMINO-1-[3-(TRIFLUOROMETHYL)-5H,6H,7H,8H-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7-YL]-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; (2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-AMINE; CHEBI:40237; (R)-3-AMINO-1-(3-(TRIFLUOROMETHYL)-5,6-DIHYDRO-[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL)-4-(2,4,5-TRIFLUOROPHENYL)BUTAN-1-ONE; Janumet; Sitagliptin phosphate; Januvia (TN); Sitagliptin (PropINN); Januvia (merck & Co); (3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; (3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one; Sitagliptin/atovastatin
Indication
Disease Entry ICD 11 Status REF
Cystic fibrosis CA25 Approved [1]
Non-insulin dependent diabetes 5A11 Approved [1]
Renal hypoplasia Approved [1]
Type-2 diabetes 5A11 Approved [2]
Peripheral arterial disease BD4Z Phase 1/2 [3]
Therapeutic Class
Hypoglycemic Agents
Cross-matching ID
PubChem CID
4369359
ChEBI ID
CHEBI:40237
CAS Number
486460-32-6
TTD ID
D0U2JP
VARIDT ID
DR00254
INTEDE ID
DR1490
ACDINA ID
D00628

Full List of Drug Formulations Containing This Drug

Sitagliptin 100 mg tablet
Company Formulation ID FDA Description
Physicians Total Care F20275 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycol
Lake Eire Medical & Surgical Supply DBA Quality Care Products F20278 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycols
A-S Medication Solutions; Cardinal Health; Clinical Solutions Wholesale F20274 Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
A-S Medication Solutions; Merck Sharp & Dohme F20276 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
RemedyRepack F20277 Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
------------------------------------------------------------------------------------
Sitagliptin 50 mg tablet
Company Formulation ID FDA Description
Physicians Total Care F20280 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Cellulose, microcrystalline; Polyethylene glycol
Avera McKennan Hospital; Cardinal Health; Merck Sharp & Dohme F20281 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
Cardinal Health F20282 Sodium stearyl fumarate; Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Polyvinyl alcohol; Calcium phosphate, dibasic, anhydrous; Cellulose, microcrystalline; Polyethylene glycols
------------------------------------------------------------------------------------
Sitagliptin 25 mg tablet
Company Formulation ID FDA Description
Avera McKennan Hospital; Merck Sharp & Dohme F20279 Sodium stearyl fumarate; Magnesium stearate; Anhydrous dibasic calcium phosphate; Ferric oxide red; Ferric oxide yellow; Talc; Titanium dioxide; Croscarmellose sodium; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified
------------------------------------------------------------------------------------

References

1 Sitagliptin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6286).
3 ClinicalTrials.gov (NCT01619332) Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763. U.S. National Institutes of Health.